Eli Lilly and Company $LLY Stock Bought by Winslow Capital Management LLC

Eli Lilly and Company logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Winslow Capital Management increased its Eli Lilly stake by 31.7% in the third quarter, adding 219,831 shares to hold 913,455 shares worth about $1.06 billion.
  • Other institutional investors also adjusted or increased their holdings, and hedge funds and institutions collectively own 82.53% of Lilly’s shares.
  • Lilly’s latest quarterly results topped expectations: earnings per share were $7.48 versus a $5.71 consensus, while revenue rose 38.6% year over year to $24.4 billion. Analysts’ average rating is “Moderate Buy,” with an average price target of $1,422.
  • Interested in Eli Lilly and Company? Here are five stocks we like better.

Winslow Capital Management LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 31.7% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 913,455 shares of the company's stock after purchasing an additional 219,831 shares during the quarter. Eli Lilly and Company accounts for 3.8% of Winslow Capital Management LLC's investment portfolio, making the stock its 6th biggest holding. Winslow Capital Management LLC owned approximately 0.10% of Eli Lilly and Company worth $1,056,941,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of LLY. Coastal Bridge Advisors LLC purchased a new stake in Eli Lilly and Company in the second quarter valued at approximately $2,959,000. Birinyi Associates Inc. raised its position in Eli Lilly and Company by 32.6% in the third quarter. Birinyi Associates Inc. now owns 1,460 shares of the company's stock valued at $1,689,000 after purchasing an additional 359 shares during the period. Bridges Investment Management Inc. lifted its position in shares of Eli Lilly and Company by 38.5% during the third quarter. Bridges Investment Management Inc. now owns 35,294 shares of the company's stock worth $40,838,000 after purchasing an additional 9,815 shares in the last quarter. Bernicke Wealth Management Ltd. acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $5,001,000. Finally, Mosaic Family Wealth Partners LLC boosted its stake in Eli Lilly and Company by 70.6% during the 2nd quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company's stock valued at $4,144,000 after acquiring an additional 1,430 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Latest Eli Lilly and Company News

Investors following LLY have been watching these news items:

  • Positive Sentiment: Lilly is expanding its oncology research through the acquisition of Calytrix Bio and a multi-target collaboration with Stipple Bio. The deals add programs and research capabilities, though their financial impact will depend on development progress. Article: Eli Lilly expands its oncology research platform
  • Neutral Sentiment: Recent updates cover studies of brenipatide, LY3839056, tirzepatide, and the cost of Alzheimer’s care. The reports describe study activity or updates, but the supplied information does not identify new efficacy results, so their near-term effect on valuation is unclear. Article: Lilly tests brenipatide in a depression study
  • Negative Sentiment: Some coverage warns that Lilly’s roughly $1.4 trillion valuation leaves substantial expectations embedded in the shares. That could make the stock more sensitive to any slowdown in growth or disappointing clinical results. Article: Eli Lilly’s valuation is heavy with hope

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. HSBC lifted their price target on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a "reduce" rating in a research note on Thursday, September 10th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $1,600.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, November 17th. Weiss Ratings raised Eli Lilly and Company from a "buy (b)" rating to a "buy (b+)" rating in a research note on Friday, November 13th. Guggenheim boosted their price target on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a "buy" rating in a research report on Friday, September 18th. Finally, BMO Capital Markets restated an "outperform" rating and issued a $1,650.00 price objective on shares of Eli Lilly and Company in a report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $1,422.00.

Get Our Latest Report on LLY

Insider Activity at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,346.40 on Friday. The company has a market capitalization of $1.27 trillion, a price-to-earnings ratio of 43.70, a P/E/G ratio of 1.61 and a beta of 0.40. Eli Lilly and Company has a 1-year low of $850.51 and a 1-year high of $1,475.25. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The stock's fifty day simple moving average is $1,268.06 and its 200-day simple moving average is $1,119.25.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The firm had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. During the same period in the prior year, the business earned $7.02 EPS. The business's revenue for the quarter was up 38.6% on a year-over-year basis. On average, sell-side analysts predict that Eli Lilly and Company will post 35.73 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company's dividend payout ratio is 22.46%.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Eli Lilly and Company Right Now?

Before you consider Eli Lilly and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.

While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines